DOI:
10.1055/s-00000007
Aktuelle Urologie
LinksClose Window
References
Nitti VW, Chapple CR, Walters C. et al.
Safety and tolerability of the beta3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial.
Int J Clin Pract 2014;
68: 972-985
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.